- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT04905069
Effektiviteten av SpaceOAR Vue-systemet hos patienter med prostatacancer som behandlas med stereootaktisk kroppsstrålbehandling (SABRE)
To demonstrate the effectiveness of the SpaceOAR Vue System in reducing late gastrointestinal (GI) toxicity in subjects undergoing Stereotactic Body Radiotherapy (SBRT) to treat prostate cancer.
Studieöversikt
Status
Betingelser
Intervention / Behandling
Detaljerad beskrivning
This study is designed to evaluate the effectiveness of the SpaceOAR Vue System in reducing late gastrointestinal (GI) toxicity in participants undergoing Stereotactic Body Radiotherapy (SBRT) for the treatment of prostate cancer.
Studietyp
Inskrivning (Faktisk)
Fas
- Inte tillämpbar
Kontakter och platser
Studieorter
-
-
New South Wales
-
Waratah, New South Wales, Australien, 2298
- Calvary Mater Newcastle
-
-
Queensland
-
Woolloongabba, Queensland, Australien, 4102
- Princess Alexandra Hospital - ROPAIR
-
-
Western Australia
-
Nedlands, Western Australia, Australien, 6009
- Sir Charles Gairdner Hospital
-
-
-
-
-
Levallois-Perret, Frankrike, 92300
- Institut de Radiothérapie & Radiochirurgie HARTMANN
-
-
Cedex
-
Villejuif, Cedex, Frankrike, 94805
- Institut Gustave Roussy
-
-
-
-
Florida
-
Fort Myers, Florida, Förenta staterna, 33908
- GenesisCare USA
-
Tampa, Florida, Förenta staterna, 33609
- Florida Urology Partners, LLC
-
-
Kansas
-
Kansas City, Kansas, Förenta staterna, 66160
- Kansas University Medical Center
-
-
Michigan
-
Troy, Michigan, Förenta staterna, 48098
- GenesisCare USA
-
-
New Jersey
-
Bloomfield, New Jersey, Förenta staterna, 07003
- New Jersey Urology, a Summit Health Company
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, Förenta staterna, 15232
- University of Pittsburgh Medical Center
-
-
South Carolina
-
Myrtle Beach, South Carolina, Förenta staterna, 29572
- Dr. John Sylvester
-
-
-
-
-
Cork, Irland, T12 DV56
- Bon Secours Radiotherapy Cork
-
-
-
-
-
Parma, Italien, 43126
- Azienda Ospedaliero Universitaria di Parma
-
Rome, Italien
- Policlinico Universitario Agostino Gemelli
-
Verona, Italien, 37024
- IRCCS Ospedale Sacro Cuore Don Calabria
-
-
-
-
-
Basel, Schweiz, CH-4031
- University Hospital Basel
-
Bern, Schweiz, 3010
- Inselspital - University Hospital Bern
-
-
-
-
-
Barakaldo, Spanien, 48903
- Hospital Universitario Cruces
-
Madrid, Spanien, 28002
- GenesisCare, Hospital San Francisco de Asis
-
Madrid, Spanien
- Hospital Universitario Ramón y Cajal
-
-
-
-
-
Belfast, Storbritannien, BT9 7AB
- Belfast City Hospital
-
Bristol, Storbritannien, BS2 8ED
- Bristol Haematology and Oncology Centre
-
London, Storbritannien, SW3 6JJ
- Royal Marsden Hospital
-
Norwich, Storbritannien, NR4 7UY
- Norfolk and Norwich University Hospital NHS Trust
-
Plymouth, Storbritannien, PL6 8DH
- Derriford General Hospital
-
-
Surrey
-
Guildford, Surrey, Storbritannien, GU27XX
- Royal Surrey County Hospital NHS Foundation Trust
-
-
Wales
-
Cardiff, Wales, Storbritannien, CF14 2TL
- Velindre Cancer Centre
-
-
-
-
-
Bonn, Tyskland, D-53129
- MEDICLIN Robert Janker Klinik
-
Nuremberg, Tyskland, 90419
- Klinikum Nurnberg Nord
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria:
- Age ≥ 18 years old.
- Subjects must have pathologically confirmed (by routine hematoxylin and eosin (H&E) staining) invasive adenocarcinoma of the prostate and been planning to undergo SBRT.
- Subjects must have intermediate risk prostate cancer as defined by the presence of one or more of the following:
- Clinical Stage T2b - T2c (AJCC 6th edition) tumor
- Gleason Score 7 as determined from a biopsy taken within 9 months preceding Enrollment (randomization)
- Demonstrated blood PSA levels 10-20 ng/ml as measured within 6 months preceding Enrollment (randomization) and prior to commencing androgen deprivation therapy (ADT)
- Subject or authorized representative was informed of the nature of the study and provided written informed consent, approved by the appropriate Institutional Review Board (IRB)/Ethics Committee (EC) of the respective clinical site.
Exclusion Criteria:
- Prostate >80 cc documented within 9 months preceding Enrollment (randomization)
- Clinical stage T3 or T4 (AJCC 6th edition) tumor
- Blood PSA level >20 ng/ml as measured within 6 months preceding Enrollment (randomization) and prior to commencing androgen deprivation therapy (ADT)
- Gleason Score ≥ 8 as determined from a biopsy taken within 9 months preceding Enrollment (randomization)
- Subjects who had MRI evidence of gross posterior extracapsular extension (ECE) of the prostate cancer. (Note: MRI should be from within 9 months preceding Enrollment (randomization). If MRI is contraindicated, a digital rectal exam may be performed to confirm the absence of gross posterior ECE)
- Subjects who had metastatic disease, other ongoing cancers which were treated during the study or subjects for whom pelvic lymph node radiotherapy was planned.
- Subjects with any prior invasive malignancy (except non-melanomatous skin cancer) unless the subject had been disease free for a minimum of 3 years.
- History of prostatectomy, transurethral prostate surgery (e.g. TUNA, TUMT, TURP) if performed within 1 year prior to screening, other local prostate cancer therapy (e.g., cryotherapy or brachytherapy) or previous pelvic irradiation at any time prior to screening.
- History of prior pelvic surgery requiring low anterior or abdominoperineal resections or rectal surgery.
- History of or active inflammatory bowel disease (IBD) such as Crohn's disease or ulcerative colitis.
- History of or current perirectal disease that may interfere with interpretation of study outcomes including anal or perianal diseases such as fistula.
- Bleeding hemorrhoids requiring medical intervention within the prior three months.
- Diagnosed active bleeding disorder or a clinically significant coagulopathy. Note: Patients on anticoagulants may be included if the anticoagulant medication can be discontinued for index procedure.
- Active inflammatory or infectious process involving the perineum, gastrointestinal (GI) or urinary tract based on positive diagnosis or suspected diagnosis in the presence of fever >38⁰ C, WBC > 12,000/uL.
- Compromised immune system or prior diagnoses for human immunodeficiency virus (HIV) (with a detectable viral load within the last 6 months)/acquired immunodeficiency syndrome (AIDS) or autoimmune disease.
- If a subject was enrolled in another investigational drug or device trial that had not completed the primary endpoint or that clinically interfered with this study.
- Unable to comply with the study requirements or follow-up schedule.
- Any condition the Investigator believed would interfere with the intent of the study or would make participation not in the best interest of the patient.
- Known iodine sensitivity or allergy
- Known polyethylene glycol (PEG) sensitivity or allergy
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Förebyggande
- Tilldelning: Randomiserad
- Interventionsmodell: Parallellt uppdrag
- Maskning: Ingen (Open Label)
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Inget ingripande: No-Spacer Control
Subjects will receive radiotherapy without the use of the SpaceOAR Vue. |
|
|
Experimentell: SpaceOAR Vue
Subjects will receive radiotherapy following injection of the SpaceOAR Vue hydrogel. |
The SpaceOAR Vue System is intended to temporarily position the anterior rectal wall away from the prostate during radiotherapy for prostate cancer and in creating this space it is the intent of the SpaceOAR Vue System to reduce the radiation dose delivered to the anterior rectum. The SpaceOAR Vue System is composed of biodegradable material, maintains space for the entire course of prostate radiotherapy treatment and is completely absorbed by the patient's body over time. |
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Late Gastrointestinal (GI) Toxicity
Tidsram: 3 to 24 months post-SBRT initiation
|
Proportion of subjects experiencing late GI toxicity after SBRT treatment with or without placement of the SpaceOAR Vue System hydrogel. Late GI toxicity is defined as the occurrence of a Grade 2 or greater GI adverse event (NCI CTCAE v4) between 3- and 24-months post-SBRT initiation |
3 to 24 months post-SBRT initiation
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
EPIC-26 bowel score
Tidsram: 24 months post-SBRT initiation
|
Proportion of subjects experiencing a decrease in EPIC-26 bowel score greater than or equal to the minimal important difference (MID) in EPIC-26 bowel score from baseline to 24 months post-SBRT initiation. |
24 months post-SBRT initiation
|
Samarbetspartners och utredare
Sponsor
Utredare
- Huvudutredare: Suneil Jain, MB, BCh, PhD, Queen's University, Belfast
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Primärt slutförande (Beräknad)
Avslutad studie (Beräknad)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Nyckelord
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- U0702
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
produkt tillverkad i och exporterad från U.S.A.
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .